Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from FTC/TDF to F/TAF in virologically suppressed adults with HIV-1
2013-005138-39Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Switch to F/TAF with Continue FTC/TDF (2 arms). Primary endpoint: Virologic suppression at Week 48. Started Mar 2014; status: completed.
02
Drugs
emtricitabinetenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2013-005138-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005138-39.